BIIB vs VRTX: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
VRTX is the larger of the two ($139.92B market cap): the incumbent the market prices for continued execution (27.08x forward earnings, beta 0.28). BIIB is the smaller challenger ($36.73B), cheaper on forward earnings (15.26x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
BIIB vs VRTX: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BIIB | VRTX | What it tells you |
|---|---|---|---|
| Market cap | $36.73B | $139.92B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 15.26 | 27.08 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 107.56 | 32.17 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.09 | 0.28 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 91% of range | 90% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.94 | 6.91 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: BIIB is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how BIIB and VRTX affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BIIB and VRTX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BIIB and VRTX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Biogen (BIIB) do?
Biogen is a Cambridge, Massachusetts biotechnology company built on neuroscience. Its historic core is multiple sclerosis (Tysabri, Tecfidera, Vumerity), and it co-developed the spinal muscular atrophy drug Spinraza with Ionis. Its growth story now centers on Leqembi, the Alzheimer's antibody it markets with partner Eisai, alongside newer rare-disease products Skyclarys (Friedreich's ataxia) and Qalsody (ALS). In 2026 it closed the roughly $5.6 billion acquisition of Apellis Pharmaceuticals, adding the retinal drug Syfovre for geographic atrophy and Empaveli for rare blood and kidney diseases. Beyond neuroscience it is pushing into immunology, where litifilimab (which holds FDA Breakthrough Therapy Designation in cutaneous lupus) reported sustained 52-week skin improvement in the AMETHYST study in late September 2026.
What does Vertex Pharmaceuticals (VRTX) do?
Vertex Pharmaceuticals is a Boston-based biotechnology company that designs medicines targeting the root molecular cause of serious diseases rather than only their symptoms. Its foundation is cystic fibrosis (CF), a genetic disease in which a defective CFTR protein disrupts salt and water movement in cells, damaging the lungs and other organs. Vertex developed the first drugs that correct the underlying protein defect, progressing from Kalydeco to Orkambi and Symdeko and then to the breakthrough triple-combination Trikafta (marketed as Kaftrio in Europe), which treats the large majority of CF patients. In late 2024 it began rolling out Alyftrek, a next-generation once-daily successor designed to extend that franchise and its patent protection. Because CF is a rare disease with essentially no competing root-cause therapy, Vertex has enjoyed pricing power and durable, high-margin revenue.
BIIB vs VRTX: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- BIIB drivers: Leqembi Alzheimer's ramp; Rare-disease and new-product portfolio.
- VRTX drivers: A durable, high-margin cystic fibrosis near-monopoly; Journavx opens a large non-opioid pain market.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The legacy MS business (Tecfidera, Tysabri) continues to decline against generics and biosimilars. For VRTX, the central risk is revenue concentration: cystic fibrosis still accounts for the overwhelming majority of Vertex's sales, so any disruption, whether a safety signal, a competing modulator, or pricing pressure, would hit the core disproportionately, and the newer products remain small by comparison.
BIIB or VRTX: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BIIB if you believe its drivers more; VRTX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BIIB and VRTX guides.
BIIB vs VRTX: the full fundamentals
BIIB. Biogen trades at about 14 times forward earnings, still below many large-cap drugmakers, while the trailing P/E near 42 reflects GAAP charges tied to the Apellis deal rather than the underlying run rate. Analysts expect 2026 EPS of about $12.53 and a rebound to about $16.52 in 2027, and the average price target of about $244 sits only slightly above the current price after the rally. The October 28 report (consensus EPS about $2.00) is the next check on whether the beats continue.
VRTX. As of October 16, 2026, Vertex trades near 29 times trailing and 25 times forward earnings, a premium to the large-cap pharma average that reflects its high margins and near-monopoly economics in cystic fibrosis plus expectations for pain, cell therapy and now endocrinology. The roughly $10 billion Crinetics purchase means part of the valuation debate has moved from unproven pipeline assets to whether an acquired franchise can earn back its price. Vertex does not pay a dividend, so returns depend on earnings growth and the multiple; Q3 results on November 2 are expected to carry deal-related costs.
Headline figures (approximate, October 2026): BIIB shows revenue (ttm) ~$10.0B, q2 2026 revenue growth ~3% YoY, q2 2026 non-gaap eps ~$3.60 (vs ~$2.03 est.), net income (ttm) ~$835M (~8% margin); VRTX shows revenue (ttm) ~$12.6 billion, revenue growth (q2 2026) ~12.5% year over year, margins (ttm) ~38% operating, ~35% net, net income (ttm) ~$4.4 billion; EPS ~$17.17.
The bottom line: BIIB vs VRTX
BIIB and VRTX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BIIB and VRTX exposure against your real portfolio. It is not an investment adviser.
Wondering how BIIB or VRTX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Biogen with AI
Connect the broker you already use and ask Walnut's AI how BIIB fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between BIIB and VRTX?
+
Biogen is a Cambridge, Massachusetts biotechnology company built on neuroscience. Vertex Pharmaceuticals is a Boston-based biotechnology company that designs medicines targeting the root molecular cause of serious diseases rather than only their symptoms. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BIIB or VRTX the better stock?
+
Neither is universally better. VRTX is the larger incumbent; BIIB is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BIIB or VRTX?
+
On forward P/E (as of November 2026), BIIB trades at 15.26x and VRTX at 27.08x, so BIIB is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BIIB and VRTX?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BIIB vs VRTX?
+
BIIB: The legacy MS business (Tecfidera, Tysabri) continues to decline against generics and biosimilars. Leqembi faces direct competition from Eli Lilly's Kisunla and lingering questions about diagnostic access, infusion logistics, and payer coverage, so its ramp could disappoint. Large acquisitions like Apellis add integration and execution risk, raised debt to about $8.4 billion, and carry contingent value payments tied to Syfovre sales that create uncertain future costs; GAAP net income over the last twelve months was only about $835 million, which is why the trailing P/E sits near 42. Biotech pipelines carry binary clinical and regulatory outcomes, and the upcoming lupus readouts are exactly that kind of event. After a 66% one-year rally to near the 52-week high, the share price leaves less room for disappointment than the old discount did, and consensus still expects 2026 EPS of about $12.53, down about 18% from 2025. VRTX: The central risk is revenue concentration: cystic fibrosis still accounts for the overwhelming majority of Vertex's sales, so any disruption, whether a safety signal, a competing modulator, or pricing pressure, would hit the core disproportionately, and the newer products remain small by comparison. Clinical and regulatory risk is elevated because the growth thesis depends on pipeline programs (zimislecel in type 1 diabetes, suzetrigine in chronic pain, inaxaplin in kidney disease) that could fail in trials or face approval delays, as happened with an earlier pain candidate. Casgevy's ramp is slow because gene therapy requires specialized centers and lengthy patient preparation, so near-term contribution is modest. The stock also trades at a premium valuation that prices in successful diversification, meaning disappointments can trigger sharp derating, and drug-pricing policy and eventual CF patent expirations are long-term overhangs. The Crinetics acquisition adds integration and launch risk: Vertex paid about $10 billion for a franchise whose peak-sales case above $5 billion still depends on Palsonify's uptake and on atumelnant succeeding in Phase 3.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BIIB or VRTX; figures are approximate and dated (as of November 2026). Verify current data before investing.